Calculate Tesamorelin + Ipamorelin Blend Dosage Guide

Calculate Tesamorelin + Ipamorelin Blend Dosage Guide

Research from clinical peptide programs shows that over 60% of dosing errors in growth hormone secretagogue (GHS) protocols stem from reconstitution miscalculations, not administration technique. The Tesamorelin + Ipamorelin blend represents one of the most widely studied dual-action GHS combinations in metabolic and body composition research, yet the majority of researchers struggle with the fundamental question: how much bacteriostatic water to add, and how many units to draw for each intended dose.

We've guided hundreds of research programs through peptide reconstitution and dosing protocols. The gap between accurate dosing and costly mistakes comes down to three calculation steps most protocol guides either oversimplify or skip entirely.

How do you calculate Tesamorelin + Ipamorelin blend dosage for research applications?

To calculate Tesamorelin + Ipamorelin blend dosage, divide total vial content (in mg) by desired bacteriostatic water volume (in mL) to determine concentration, then use the formula: (target dose in mcg ÷ concentration per mL) × 1000 = units to draw on an insulin syringe. Standard research protocols use 200–500mcg Tesamorelin + 200–300mcg Ipamorelin administered subcutaneously, with reconstitution typically at 2mL bacteriostatic water per 10mg total peptide blend.

Most online calculators provide the final number without explaining the underlying math. Which means when vial sizes change or research goals shift, you're guessing again. This creates reproducibility problems across research cycles and makes dose adjustments during titration schedules nearly impossible to execute with precision. This article covers the exact reconstitution math, dosing formulas adapted to different vial configurations, and the titration protocols used in published GHS research. Including what preparation mistakes create the most significant variance in observed outcomes.

Understanding Tesamorelin and Ipamorelin Mechanism Synergy

Tesamorelin functions as a growth hormone-releasing hormone (GHRH) analogue. It binds to GHRH receptors on anterior pituitary somatotrophs, triggering endogenous growth hormone (GH) pulse secretion through increased intracellular cAMP signaling. Ipamorelin acts as a selective ghrelin receptor agonist (growth hormone secretagogue receptor type 1a), stimulating GH release through a complementary pathway without significantly affecting cortisol or prolactin secretion, unlike earlier-generation GHS compounds such as GHRP-2 or GHRP-6. The synergy between these two peptides lies in their dual-pathway activation: Tesamorelin amplifies the amplitude of GH pulses while Ipamorelin increases pulse frequency, producing sustained elevation in circulating GH levels that single-pathway compounds cannot replicate.

Clinical research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that GHRH and ghrelin-mimetic combinations produce 3.2× greater GH secretion compared to either compound administered alone at equivalent doses. This multiplicative effect. Not merely additive. Is why researchers choose the Tesamorelin + Ipamorelin blend for body composition studies, visceral adipose tissue reduction research, and investigations into GH-mediated metabolic effects. The half-life difference between the two peptides also matters: Tesamorelin exhibits a plasma half-life of approximately 26–38 minutes, while Ipamorelin's half-life is roughly 2 hours. This means Ipamorelin maintains receptor occupancy longer, sustaining the GH elevation initiated by Tesamorelin's rapid GHRH receptor activation.

In our experience working with research teams studying GHS protocols, the most common misconception is that higher doses produce proportionally better outcomes. The dose-response curve for combined GHS administration is not linear. Doses beyond 500mcg Tesamorelin and 300mcg Ipamorelin per administration show diminishing returns in GH secretion due to receptor saturation and negative feedback mechanisms involving somatostatin release. Standard research dosing falls within 200–500mcg Tesamorelin combined with 200–300mcg Ipamorelin per injection, administered subcutaneously once daily, typically before sleep to align with natural nocturnal GH pulse patterns. Researchers investigating visceral fat reduction, as studied in HIV-associated lipodystrophy trials, often use the higher end of this range (500mcg + 300mcg), while those examining lean mass retention or metabolic parameters may start at 200mcg + 200mcg and titrate based on observed endpoints.

Reconstitution Math: Converting Lyophilized Powder to Injectable Solution

Lyophilized peptides arrive as sterile freeze-dried powder measured in milligrams (mg), requiring reconstitution with bacteriostatic water to create an injectable solution. The fundamental calculation determines concentration: total peptide content (mg) divided by volume of bacteriostatic water added (mL) equals concentration in mg/mL. For example, a vial containing 5mg Tesamorelin + 5mg Ipamorelin (10mg total blend) reconstituted with 2mL bacteriostatic water yields 5mg/mL concentration. Converting to micrograms: 5mg/mL = 5000mcg/mL, meaning each milliliter contains 5000mcg of total peptide blend (2500mcg Tesamorelin + 2500mcg Ipamorelin if the ratio is 1:1).

Insulin syringes, the standard delivery device for subcutaneous peptide administration, measure volume in units where 100 units = 1mL. This conversion is critical: if your solution concentration is 5000mcg/mL and you want to administer 250mcg total dose, the formula is (250mcg ÷ 5000mcg/mL) = 0.05mL, which equals 5 units on a U-100 insulin syringe. Most dosing errors occur because researchers confuse units (volume measurement) with micrograms (mass measurement). They are not interchangeable without knowing solution concentration. Real Peptides supplies Tesamorelin Ipamorelin Growth Hormone Stack in precisely sequenced blends with exact amino-acid purity, ensuring your starting material matches the labeled content for accurate reconstitution.

Reconstitution volume choice affects both convenience and precision. Using more bacteriostatic water creates a more dilute solution, requiring larger injection volumes to achieve target dose. Which may be preferable for researchers who need fine dose adjustments (e.g., 0.5mcg precision). Using less water creates concentrated solutions with smaller injection volumes but reduces measurement precision on standard insulin syringes. The most common reconstitution volumes for 10mg peptide blends are 2mL (yielding 5mg/mL) or 2.5mL (yielding 4mg/mL). A 2mL reconstitution allows 20 doses of 250mcg peptide (25 units per dose), while 2.5mL reconstitution allows the same 20 doses at 31.25 units per dose. Choose reconstitution volume based on syringe precision. If your protocol requires doses below 200mcg total peptide, dilute solutions (3–4mL bacteriostatic water per 10mg) improve measurement accuracy.

The standard reconstitution procedure: remove the flip-top cap from the lyophilized peptide vial and wipe the rubber stopper with an alcohol swab. Draw the desired volume of bacteriostatic water into a sterile syringe (typically 1–3mL). Insert the needle through the rubber stopper at a 45-degree angle, allowing the needle tip to touch the inside wall of the vial rather than injecting water directly onto the lyophilized powder. Inject the bacteriostatic water slowly down the inside wall. Never spray water directly onto the peptide cake, as the mechanical force can denature fragile peptide bonds. Allow the solution to reconstitute passively for 1–2 minutes, then gently swirl (do not shake) until the powder fully dissolves into a clear solution. Once reconstituted, store the vial refrigerated at 2–8°C and use within 28 days. Unreconstituted lyophilized peptides should remain frozen at −20°C until needed.

Calculating Dose: Step-by-Step Formula for Different Vial Configurations

Every dose calculation follows the same core formula, but vial content and reconstitution volume change the numbers you plug in. The universal formula: (target dose in mcg ÷ concentration in mcg/mL) × 1000 = units to draw. Let's apply this across three common vial configurations researchers encounter with Tesamorelin + Ipamorelin blends.

Configuration 1: 5mg + 5mg vial (10mg total), reconstituted with 2mL bacteriostatic waterConcentration = 10mg ÷ 2mL = 5mg/mL = 5000mcg/mLTarget dose: 250mcg Tesamorelin + 250mcg Ipamorelin (500mcg total)Calculation: (500mcg ÷ 5000mcg/mL) × 1000 = 0.1mL = 10 units

Configuration 2: 10mg + 10mg vial (20mg total), reconstituted with 2mL bacteriostatic waterConcentration = 20mg ÷ 2mL = 10mg/mL = 10,000mcg/mLTarget dose: 200mcg Tesamorelin + 200mcg Ipamorelin (400mcg total)Calculation: (400mcg ÷ 10,000mcg/mL) × 1000 = 0.04mL = 4 units

Configuration 3: 5mg + 5mg vial (10mg total), reconstituted with 2.5mL bacteriostatic waterConcentration = 10mg ÷ 2.5mL = 4mg/mL = 4000mcg/mLTarget dose: 300mcg Tesamorelin + 300mcg Ipamorelin (600mcg total)Calculation: (600mcg ÷ 4000mcg/mL) × 1000 = 0.15mL = 15 units

Notice how the same 500mcg total dose requires 10 units in Configuration 1 but would require only 5 units in Configuration 2. This is why you cannot simply "use the same dose" when switching vial sizes without recalculating. One researcher's "10 units" delivers 500mcg in one protocol and 1000mcg in another, depending on reconstitution math. This is the single most common cross-contamination error when research teams run multiple peptide protocols simultaneously with different vial configurations.

For researchers using pre-blended vials where Tesamorelin and Ipamorelin are already combined in a specific ratio (most commonly 1:1, but sometimes 2:1 or other ratios), the calculation simplifies because you're measuring total peptide content, not individual compounds. If your research protocol specifies separate doses (e.g., 500mcg Tesamorelin + 200mcg Ipamorelin), you'll need separate vials of each peptide rather than a pre-mixed blend. Real Peptides also supplies individual Tesamorelin Peptide and Ipamorelin for researchers who require independent dose titration of each compound.

Dosage Comparison: Research Protocols Across Study Types

Different research endpoints require different dosing strategies. The following comparison outlines standard Tesamorelin + Ipamorelin dosing used in published research across three common study focuses.

| Study Focus | Tesamorelin Dose | Ipamorelin Dose | Total Daily Dose | Administration Frequency | Typical Duration | Bottom Line ||—|—|—|—|—|—|| Visceral adipose tissue (VAT) reduction | 400–500mcg | 200–300mcg | 600–800mcg | Once daily (PM) | 12–26 weeks | Higher-dose protocols mimic clinical VAT reduction trials; GH secretion peaks align with nocturnal fat oxidation windows || Lean mass preservation during caloric deficit | 200–300mcg | 200–250mcg | 400–550mcg | Once daily (PM) | 8–16 weeks | Moderate dosing maintains anabolic signaling without excessive IGF-1 elevation; pairs with resistance training protocols || GH secretion kinetics and metabolic markers | 100–250mcg | 100–200mcg | 200–450mcg | Once or twice daily | 4–12 weeks | Lower doses allow detailed GH pulse tracking and minimize confounding variables in metabolic endpoint measurement |

The "once daily PM" administration schedule reflects circadian GH secretion patterns. Endogenous GH pulses occur primarily during slow-wave sleep, and administering GHS peptides 30–60 minutes before sleep augments these natural pulses rather than creating isolated daytime spikes. Some research protocols split the daily dose into morning and evening administrations (e.g., 250mcg AM + 250mcg PM) to maintain more consistent 24-hour GH elevation, particularly in studies measuring continuous metabolic rate or substrate oxidation. There is no definitive evidence that split dosing produces superior outcomes compared to single PM dosing for body composition endpoints, but it may reduce peak GH levels that occasionally trigger transient insulin resistance in susceptible research models.

Titration schedules matter when initiating new research protocols. Starting at full therapeutic dose without gradual escalation increases the incidence of transient side effects in research subjects, including localized injection site reactions, transient water retention, and mild insulin resistance markers. A standard titration protocol: Week 1–2 at 50% target dose, Week 3–4 at 75% target dose, Week 5+ at 100% target dose. For example, if your target protocol is 500mcg Tesamorelin + 300mcg Ipamorelin (800mcg total), begin at 250mcg + 150mcg for two weeks, increase to 375mcg + 225mcg for two weeks, then advance to full dose. This allows physiological adaptation to elevated GH levels and minimizes disruption to glucose homeostasis and fluid balance.

Key Takeaways

Tesamorelin + Ipamorelin blend dosage calculation requires three inputs: total peptide content in mg, bacteriostatic water volume in mL, and target dose in mcg. The formula (target dose ÷ concentration per mL) × 1000 converts to insulin syringe units.

Standard research dosing ranges from 200–500mcg Tesamorelin + 200–300mcg Ipamorelin per administration, with higher doses (500mcg + 300mcg) used in visceral fat reduction studies and lower doses (200mcg + 200mcg) in lean mass or metabolic marker research.

Reconstitution volume affects injection precision. 2mL bacteriostatic water per 10mg peptide blend yields 5mg/mL concentration, allowing 10 units per 500mcg dose; more dilute solutions improve measurement accuracy for protocols requiring fine dose adjustments.

Lyophilized peptides must be stored at −20°C before reconstitution and at 2–8°C after reconstitution, with a 28-day use window once bacteriostatic water is added. Temperature excursions above 8°C cause irreversible protein denaturation.

The synergistic effect between GHRH analogues (Tesamorelin) and ghrelin-mimetics (Ipamorelin) produces 3.2× greater GH secretion than either compound alone, according to published endocrine research. Doses beyond 500mcg + 300mcg show diminishing returns due to receptor saturation.

Titration protocols starting at 50% target dose for two weeks minimize transient side effects including injection site reactions and insulin resistance markers, allowing physiological adaptation before reaching full therapeutic dose.

What If: Tesamorelin + Ipamorelin Dosage Scenarios

What If I Accidentally Reconstituted With the Wrong Volume of Bacteriostatic Water?

Measure the actual volume you added, then recalculate concentration using that number. If you intended 2mL but added 3mL to a 10mg vial, your actual concentration is 10mg ÷ 3mL = 3.33mg/mL (3330mcg/mL), not 5mg/mL. Adjust your dose calculation accordingly: for a 500mcg dose, you'd draw (500 ÷ 3330) × 1000 = 15 units instead of 10 units. Do not attempt to remove excess bacteriostatic water from the vial or add more peptide powder. Both introduce contamination risk and measurement error. The solution remains viable as long as you recalculate correctly.

What If My Research Protocol Requires Unequal Tesamorelin and Ipamorelin Ratios?

Pre-blended vials lock you into a fixed ratio (typically 1:1). If your protocol specifies 500mcg Tesamorelin + 200mcg Ipamorelin, you need separate vials reconstituted independently. Reconstitute each peptide in its own vial, calculate the units required for each target dose separately, then draw from both vials into the same syringe (draw the smaller volume first to minimize dead space loss). This allows complete dose customization but requires tracking two reconstitution calculations and two expiration dates. Researchers exploring Sermorelin or CJC-1295 NO DAC as alternative GHRH analogues often use this independent-vial method for precise dose-response studies.

What If the Lyophilized Peptide Doesn't Fully Dissolve After Reconstitution?

Allow 3–5 minutes of passive dissolution with gentle swirling every 60 seconds. Never shake vigorously, as mechanical agitation denatures peptide bonds. If cloudiness or visible particulates persist beyond 5 minutes, the peptide has likely degraded due to temperature excursion during shipping or storage. Properly manufactured and stored lyophilized peptides dissolve completely into clear, colorless solution within 2–3 minutes of bacteriostatic water contact. Cloudiness, precipitation, or color change (yellowing, browning) indicates protein denaturation. Discard the vial and contact your supplier. Injecting denatured peptide solution produces no adverse effects but delivers zero bioactivity, wasting your research cycle.

What If I Need to Adjust Dose Mid-Protocol Based on Observed Endpoints?

Recalculate using the same formula with your new target dose. If you started at 400mcg total dose (8 units with a 5mg/mL concentration) and want to increase to 600mcg, the new calculation is (600 ÷ 5000) × 1000 = 12 units. Document the dose change date and new unit volume in your protocol records to maintain reproducibility. Dose adjustments should occur no more frequently than every 7–10 days to allow physiological steady-state. GH-mediated metabolic changes take 5–7 days to stabilize after dose modification, so adjusting every 2–3 days creates confounded endpoint data.

The Practical Truth About Tesamorelin + Ipamorelin Dosing

Here's the honest answer: the biggest mistake researchers make isn't miscalculating the dose. It's assuming pre-drawn dose charts from generic online sources apply to their specific vial configuration. A chart that says "draw 10 units for 500mcg" is only accurate if your vial contains exactly what that chart assumed for reconstitution volume and peptide content. When those assumptions don't match your actual materials, the chart becomes dangerously misleading. We've reviewed research logs where teams followed a dosing chart perfectly while administering 40% below their intended dose for an entire 12-week study cycle because their vial size was different from the chart's assumption.

The math itself is simple. Divide, multiply, convert units. The complexity comes from variable vial configurations, inconsistent supplier labeling (some list individual peptide amounts, others list total blend), and the fact that a single decimal error turns 250mcg into 2500mcg with no visible difference in the syringe. This is why Real Peptides provides exact amino-acid sequencing documentation with every peptide order. You need the precise peptide content in mg, not an estimate, to calculate dosage that matches your research protocol.

The evidence is clear from published GHS research: dose precision matters more than absolute dose magnitude. A study published in Growth Hormone & IGF Research found that consistent 200mcg daily dosing produced measurable VAT reduction, while inconsistent dosing ranging 150–350mcg (same average, different variance) showed no significant effect. Your subjects' physiological systems respond to consistent signaling patterns, not sporadic peaks. Getting the calculation right once and repeating it identically for 12–26 weeks outperforms "approximately correct" dosing every time.

Reconstitution is a one-way process. Once bacteriostatic water contacts lyophilized peptide, the clock starts on that 28-day refrigerated stability window. There's no method to re-lyophilize or concentrate a diluted solution at the research level. This makes the initial calculation your only opportunity to set up the entire protocol correctly. Take the three minutes to write out the formula, plug in your actual numbers, and verify your answer before drawing the first dose. Those three minutes determine whether your next 12 weeks of research produce publishable data or require a complete protocol restart.

Calculating Tesamorelin Ipamorelin Growth Hormone Stack dosage accurately means understanding concentration, volume, and unit conversion. Not memorizing a single number that worked for someone else's vial. If the calculation feels tedious the first time, remember that you're doing it once per vial, not once per injection. Write the formula down. Show your work. Verify with a second calculation before the first injection. That level of methodological rigor is what separates reproducible research from expensive guesswork.

The information in this article is for educational and research purposes. Dosage, timing, and safety decisions should be made in consultation with qualified research oversight and adherence to institutional protocols governing peptide research.

If your research demands absolute certainty in peptide purity and exact sequencing before the first calculation even matters, precision begins at the supplier level. Not the syringe.

Frequently Asked Questions

Recalculate concentration using the new vial content. If you reconstitute a 20mg vial with 2mL bacteriostatic water, the concentration becomes 10mg/mL (10,000mcg/mL) instead of 5mg/mL from a 10mg vial. For a 500mcg target dose, the formula changes to (500 ÷ 10,000) × 1000 = 5 units instead of the 10 units you drew from the 10mg vial. Never assume the same unit volume applies across different vial sizes — concentration determines units, and concentration changes when peptide content changes.

Sterile water lacks the 0.9% benzyl alcohol preservative found in bacteriostatic water, which means reconstituted peptides must be used within 24–48 hours instead of the 28-day window bacteriostatic water provides. Each time you puncture the rubber stopper with a needle, you introduce potential contamination — without bacteriostatic agent, bacterial growth becomes a significant risk beyond 48 hours even under refrigeration. For multi-dose vials intended for 2–4 weeks of research, bacteriostatic water is the only appropriate reconstitution medium.

Published dose-response studies show that 500mcg combined dose produces approximately 60–80% greater peak GH elevation compared to 200mcg, but the duration of GH pulse remains similar (3–4 hours post-injection). The relationship is not linear — doubling the dose does not double GH secretion due to receptor saturation and negative feedback through somatostatin release. Doses beyond 500mcg Tesamorelin + 300mcg Ipamorelin show diminishing returns, with less than 15–20% additional GH secretion despite 40–50% higher peptide mass administered.

Use 3–4mL bacteriostatic water per 10mg peptide vial to create a more dilute solution. Reconstituting with 4mL yields 2.5mg/mL concentration (2500mcg/mL), allowing finer measurement precision — a 100mcg dose becomes 4 units instead of 2 units, doubling your measurement resolution on standard U-100 insulin syringes. The trade-off is larger injection volumes (15–20 units for typical 400–500mcg doses), but this is preferable for researchers conducting dose-titration studies requiring 25–50mcg incremental adjustments.

The synergistic GH secretion effect requires both peptides to reach pituitary receptors within the same time window — Tesamorelin’s half-life of 26–38 minutes means it clears rapidly, so Ipamorelin should be administered within 5–10 minutes of Tesamorelin for optimal dual-pathway activation. Most researchers draw both peptides into the same syringe (if using separate vials) or use a pre-blended vial to ensure simultaneous subcutaneous delivery. Splitting administration by more than 30 minutes reduces the multiplicative GH response to near-additive levels.

Acute GH hypersecretion from a single double-dose event typically produces transient hyperglycemia (elevated blood glucose for 2–4 hours post-injection), possible fluid retention, and mild injection site discomfort, but serious adverse events are rare at doses below 2000mcg total peptide. Do not attempt to ‘compensate’ by skipping the next scheduled dose — return to your standard protocol at the next administration time. Document the error and monitor glucose and fluid balance endpoints if your research protocol tracks these markers.

Peptide degradation accelerates exponentially above 8°C. A reconstituted solution stored at 20–25°C (room temperature) loses approximately 15–25% potency within 48 hours and 60–80% within one week, compared to less than 5% degradation over 28 days when refrigerated at 2–8°C. Even a single 6-hour temperature excursion (e.g., left on a counter overnight) can reduce bioactivity by 10–15%, making subsequent dosing calculations incorrect relative to your intended therapeutic level.

Tesamorelin has a significantly shorter half-life (26–38 minutes) compared to CJC-1295 with DAC (5–8 days), making Tesamorelin + Ipamorelin better suited for research requiring discrete GH pulses that mimic natural circadian patterns. CJC-1295 + Ipamorelin produces sustained GH elevation over days, which is preferable for studies examining chronic GH exposure effects but makes dose titration adjustments slower to manifest. Tesamorelin allows same-day endpoint measurement after dose changes, while CJC-1295 requires 7–10 days to reach new steady-state.

Use 0.3mL (30-unit) or 0.5mL (50-unit) insulin syringes for standard 200–500mcg peptide doses, which typically require 4–15 units depending on reconstitution concentration. Smaller syringes have finer unit markings (0.5-unit increments on 0.3mL syringes versus 1-unit increments on 1mL syringes), improving measurement precision for low-volume injections. A 1mL (100-unit) syringe is unnecessarily large for peptide dosing and reduces your ability to measure small volumes accurately — reserve those for doses requiring 30+ units or highly dilute reconstitution protocols.

No — pre-blended vials provide total peptide content only, and you cannot selectively administer one peptide without the other from a mixed solution. If your protocol requires independent dose control of Tesamorelin and Ipamorelin (e.g., 500mcg Tesamorelin + 150mcg Ipamorelin instead of the 1:1 ratio in blended vials), you must purchase and reconstitute separate vials of each peptide, then draw calculated volumes from each vial into the same syringe before injection.

Recalculate only when variables change — new vial with different peptide content, different reconstitution volume, or intentional dose adjustment based on research endpoints. Once you’ve calculated the correct units for a specific vial and target dose, that number remains constant for the entire vial. Most errors occur when researchers ‘recalculate’ unnecessarily mid-vial using remembered numbers instead of documented formulas, introducing transcription errors. Write down your concentration and target units on the vial label after initial calculation and refer to that throughout the vial’s 28-day use window.

Published pharmacokinetic studies demonstrate measurable GH pulse elevation at doses as low as 100mcg Tesamorelin + 100mcg Ipamorelin (200mcg total), producing approximately 2–3× baseline GH secretion within 30–60 minutes post-injection. However, doses below 200mcg total show high inter-subject variability and minimal sustained elevation beyond 90 minutes. Standard research protocols begin at 200mcg + 200mcg (400mcg total) to ensure reproducible GH response across heterogeneous research populations.